Alta Partners

Alta Partners is a venture capital fund manager devoted exclusively to the life sciences. Historically, the firm invested out of two separate fund families. The Alta California Partners (ACP) funds were dedicated to early-stage investments, while the Alta BioPharma (ABP) series focused on later-stage private companies and early public companies. ACP IV marked Alta's shift towards a singular focus on life sciences investing, and in 2006, the firm launched Alta Partners VIII, its first stage-agnostic fund.

Robert Alexander

Director

Peter A. Hudson

MD

Dan Janney

MD

Bob More

MD

Larry Randall

CFO

AL

Adam L. Tomasi

Principal

250 past transactions

Sanarus Medical

Series C in 2003
Sanarus Medical, Inc. develops and markets minimally invasive devices for the diagnosis and treatment of breast tumors. It offers Visica treatment system for cryoablation of breast fibroadenomas; Cassi II rotational core biopsy system, an automated hand held breast biopsy device to secure contiguous biopsy samples; and ImarC tissue marker system, a line of breast tissue markers that are visible under imaging modalities. The company was founded in 1999 and is headquartered in Pleasanton, California.

eIndia

Venture Round in 2000
eIndia.com is an integrated Internet Platform company delivering content, community and commerce to the millions of people worldwide interested in Indian products and services. The company aims to be the provider of choice for various Internet-related services in India and throughout the world. eIndia.com offers a broad range of Internet products, services and solutions to Internet users, on-line advertisers and web-based enterprises through the integration of its destination network and its web solutions services.

Insulet Corporation

Series E in 2006
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Nereus Pharmaceuticals

Series A in 2000
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

aTyr Pharma, Inc.

Series C in 2009
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Aegis Semiconductor

Series E in 2009
Aegis is a privately held company that builds solutions for embedded monitoring of advanced optical networks. The company's Active Thin Films are manufactured using proven high-volume processes with demonstrated high yield and superb uniformity. Aegis's solutions benefit from the reliability of solid-state, silicon-based design, extreme scalability, and low-cost packaging architectures.

Transcarent

Series B in 2021
Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.

Vitra Bioscience

Venture Round in 2004
Vitra Bioscience, a venture-backed biotechnology company, is developing novel technologies for comprehensive cellular analysis. The Company’s strategic objective is to create breakthrough solutions that enable users to acquire more informative data in less time, allowing for better decision-making. By applying modern imaging technology with proprietary consumables and software, Vitra Bioscience intends to develop and commercialize products that turn serial steps into parallel ones providing users with a complete tool set for their individual research needs.

Plexxikon

Series B in 2004
Plexxikon, Inc. engages in the discovery and development of small molecule pharmaceuticals to treat human disease. The company's products include PLX204 for the treatment of diabetes; PLX4032 for the treatment of melanoma and colorectal cancer; and PLX5568 kinase inhibitors for the treatment of pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease. It develops a portfolio of clinical and preclinical stage programs in various therapeutic areas, including metabolic disease, such as obesity indications; oncology, such as osteolytic metastatic disease; and CNS, such as multiple sclerosis. The company’s portfolio of clinical and preclinical stage programs for other therapeutic areas include inflammation, such as systemic lupus erythematosus, inflammatory bowel disease, and osteoporosis; and cardiovascular, including hypertension and atherosclerosis.

Syntonix Pharmaceuticals

Venture Round in 2002
Syntonix discovers and develops novel, long-acting, proprietary therapeutic products using the company’s proprietary Fc-fusion proteins and other engineered ligands which bind to specific Fc receptors. These technologies, including Syntonix’ drug delivery platform technology Transceptor™, harness the body’s natural pathways for protecting antibodies against premature destruction and for transporting antibodies across cell barriers such as those in the lungs and intestines. Syntonix focuses on using these technologies to create next generation treatments for devastating chronic diseases such as hemophilia, anemia, and autoimmune disorders. Syntonix develops selected products for specialty indications, such as hemophilia, on its own. Other products will be evaluated and commercialized through partnerships with companies with established market positions. The company is headed by an experienced management team and has focused initially on using its proprietary technology to enhance existing drugs with proven safety, efficacy, and economic return. Syntonix currently occupies a 25,000 square foot state-of-the-art laboratory facility, including a cGMP clinical manufacturing suite, in Waltham, Massachusetts.

MAKO Surgical

Post in 2008
MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific osteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment. In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal. MAKO Surgical was founded in 2004 and is headquartered in Florida, USA.
Cellective Therapeutics was founded with technology created by Dr. Tom Tedder, a recognized world leader in B-cell biology and Chairman of the Department of Immunology at Duke University. Dr. Tedder's team focused on research done in B cells, cells that form an important component of the normal immune system and are hyperactive in people with autoimmune disorders. This hyperactivity of B cells can cause tissue inflammation and organ system dysfunction. With autoimmune diseases like lupus, multiple sclerosis and rheumatoid arthritis, the body actually rejects itself, as if organs were transplanted from someone else. Cellective's research focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.

Virobay

Series B in 2014
Virobay, Inc. operates as an anti-viral drug discovery and development company. It engages in developing, investigating, and creating treatments for hepatitis C, such as protease and polymerase inhibitors. The company was founded in 2006 and is headquartered in Menlo Park, California.

Syntonix Pharmaceuticals

Series B in 2002
Syntonix discovers and develops novel, long-acting, proprietary therapeutic products using the company’s proprietary Fc-fusion proteins and other engineered ligands which bind to specific Fc receptors. These technologies, including Syntonix’ drug delivery platform technology Transceptor™, harness the body’s natural pathways for protecting antibodies against premature destruction and for transporting antibodies across cell barriers such as those in the lungs and intestines. Syntonix focuses on using these technologies to create next generation treatments for devastating chronic diseases such as hemophilia, anemia, and autoimmune disorders. Syntonix develops selected products for specialty indications, such as hemophilia, on its own. Other products will be evaluated and commercialized through partnerships with companies with established market positions. The company is headed by an experienced management team and has focused initially on using its proprietary technology to enhance existing drugs with proven safety, efficacy, and economic return. Syntonix currently occupies a 25,000 square foot state-of-the-art laboratory facility, including a cGMP clinical manufacturing suite, in Waltham, Massachusetts.

Be Biopharma

Series B in 2022
Be Biopharma, Inc. develops therapeutics for diseases from engineered B-cells in the immune system. It can overcome the drawbacks of current cell and gene therapies, including the inability to provide multiple doses, unpredictable chemical reactions in some individuals, and the need for chemotherapy regimens prior to cell therapies that can be dangerous to patients. The company applies its technology to diseases, including cancer, autoimmune disorders, and infectious diseases. The company was incorporated in 2020 and is based in Cambridge, Massachusetts.

Xelerated

Series C in 2005
Xelerated Inc. operates as a fabless semiconductor company. The company provides HX devices that offer wirespeed performance and cover a range of applications from carrier backbone platforms to access aggregation and enterprise switching systems; and Xelerator devices, which are network processors. It also offers a Software Development Kit that delivers an integrated development environment for developing, simulating, debugging, and testing forwarding plane applications for Xelerator network processors, as well as supports Xelerated's HX carrier Ethernet network processors and AX programmable Ethernet switches. In addition, the company provides Reference Design Kits, which are network processor development platforms for Xelerator network processors; and Precision Time Solution, which provides hardware and software support for Precision Time Protocol and Synchronous Ethernet. Further, it offers solutions for data aware transport platforms, switches/routers, metro Ethernet switches, and access equipment. The company was formerly known as Xelerated Packet Devices and changed its name to Xelerated Inc. in January 2002. The company was founded in 2000 and is headquartered in Santa Clara, California with additional offices in Tel Aviv, Israel; Beijing, China; and Stockholm, Sweden.
PamGene has a unique proprietary array-based platform to measure the activities of kinases & nuclear receptors, enabling deeper understanding of drug interactions with these important classes of signalling molecules. PamGene's patented technology finds a wide range of applications including lead identification and optimization, (pre) clinical translational research and biomarker development.

ABIONYX Pharma SA

Series A in 2005
ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

Cotherix

Series C in 2003
Cotherix is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. Ventavis, our lead product candidate, is an inhaled formulation of iloprost.
Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.

TransMedics Group, Inc.

Series C in 2006
TransMedics, Inc. operates as a medical technology company. It offers organ care system, a multi-organ preservation technology that mirrors human physiology, minimizes ischemia, and provides the ability to optimize the organ during transport. The company is headquartered in Andover, Massachusetts.

Aegerion Pharmaceuticals

Series B in 2007
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.

Nereus Pharmaceuticals

Series D in 2005
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

eGenesis

Series A in 2017
Egenesis Inc., a biotechnology company, operates as a gene editing and genome engineering that develops human transplantable organs, tissues, and cells. It offers a gene editing platform for developing human compatible organs. The company also provides development, such as gene engineering, single cell cloning, somatic cell nuclear/embryo transfer, organ procurement, and transplantation. The company was incorporated in 2015 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Phenomix

Series C in 2007
As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

Agensys

Series D in 2007
Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.

Tacit Knowledge

Series A in 2004
Tacit Knowledge is the digital commerce consultancy that delivers Silicon Valley innovation to retail organizations around the world. Founded in 1997 by a group of software engineers, Tacit implements packaged applications and builds custom software for globally recognized multichannel organizations, including some of Internet Retailer's Top 25. The company is headquartered in San Francisco with offices in New York, London, Guadalajara, and Chisinau.

Xelerated

Venture Round in 2003
Xelerated Inc. operates as a fabless semiconductor company. The company provides HX devices that offer wirespeed performance and cover a range of applications from carrier backbone platforms to access aggregation and enterprise switching systems; and Xelerator devices, which are network processors. It also offers a Software Development Kit that delivers an integrated development environment for developing, simulating, debugging, and testing forwarding plane applications for Xelerator network processors, as well as supports Xelerated's HX carrier Ethernet network processors and AX programmable Ethernet switches. In addition, the company provides Reference Design Kits, which are network processor development platforms for Xelerator network processors; and Precision Time Solution, which provides hardware and software support for Precision Time Protocol and Synchronous Ethernet. Further, it offers solutions for data aware transport platforms, switches/routers, metro Ethernet switches, and access equipment. The company was formerly known as Xelerated Packet Devices and changed its name to Xelerated Inc. in January 2002. The company was founded in 2000 and is headquartered in Santa Clara, California with additional offices in Tel Aviv, Israel; Beijing, China; and Stockholm, Sweden.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Sutro Biopharma, Inc.

Series B in 2009
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Bioventus Inc.

Venture Round in 2012
Bioventus LLC develops and/or markets orthobiologic solutions for bone fusion and osteoarthritis. Its active healing therapies product line supports accelerated and more complete healing of bone fractures, and treats the chronic pain associated with osteoarthritis; and bone healing solutions work to enhance the body’s natural healing process. The company also provides injection therapies that treat osteoarthritic joints relieve pain and help bring mobility back to the patient; and surgical orthobiologics. Its products are available through a network of distributors. The company was incorporated in 2011 and is based in Durham, North Carolina. Bioventus LLC operates as a subsidiary of Bioventus Inc.

Paladina Health

Venture Round in 2022
Everside Health is a direct primary care provider offering convenient on-site, near-site, and virtual care for its members. Everside’s data-driven, patient-centric healthcare delivery model aligns incentives to benefit the patient, the physician, and the benefit provider, all while reducing the total cost of care.

Kite Pharma, Inc.

Series A in 2013
Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. These potential therapies could provide novel strategies for the treatment and management of a wide range of tumor types.

VertiFlex

Series C in 2008
VertiFlex, Inc., a medical device company, provides minimally invasive and motion preserving spinal surgery technologies in the United States and internationally. The company offers superion interspinous spacer, a percutaneous titanium implant that fits between the spinous processes in the lumbar spine. Its Superion is a motion-preserving interspinous spacer for the treatment of moderate spinal stenosis. Vertiflex Inc was founded in 2005 and is headquartered in California, USA.

Netli

Venture Round in 2006
Netli provides a number of corporate network and Internet services, including hosting, storage, and security services. Customers include Hewlett-Packard , Motorola, and Millipore. Netli has received equity financing from Reed Elsevier Ventures, Morgenthaler Ventures, Bessemer Venture Partners, and Alta Partners, among others. The company has offices in the US and Hong Kong. Netli was acquired by content and application acceleration specialist Akamai Technologies in 2007.

Intradigm Corporation

Series B in 2009
Private biotechnology company that develops systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's expertise in drug development and delivery serves as the foundation of Intradigm RNAi platform. In particular, the company proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product.

Ceregene

Series C in 2007
Ceregene is a private, San Diego-based biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Their clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor, which is about to enter Phase 2 studies for the treatment of Alzheimer's disease, and CERE-120, which recently completed a Phase 2 trial in Parkinson's disease and is currently being evaluated for future development. CERE-135 and CERE-140 are in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and ocular diseases, respectively.

Chimerix, Inc.

Series F in 2011
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Alba Therapeutics

Series A in 2005
Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba’s technology is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, asthma/COPD and acute lung injury.

Arrow Therapeutics

Venture Round in 2002
Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

Xelerated

Series D in 2007
Xelerated Inc. operates as a fabless semiconductor company. The company provides HX devices that offer wirespeed performance and cover a range of applications from carrier backbone platforms to access aggregation and enterprise switching systems; and Xelerator devices, which are network processors. It also offers a Software Development Kit that delivers an integrated development environment for developing, simulating, debugging, and testing forwarding plane applications for Xelerator network processors, as well as supports Xelerated's HX carrier Ethernet network processors and AX programmable Ethernet switches. In addition, the company provides Reference Design Kits, which are network processor development platforms for Xelerator network processors; and Precision Time Solution, which provides hardware and software support for Precision Time Protocol and Synchronous Ethernet. Further, it offers solutions for data aware transport platforms, switches/routers, metro Ethernet switches, and access equipment. The company was formerly known as Xelerated Packet Devices and changed its name to Xelerated Inc. in January 2002. The company was founded in 2000 and is headquartered in Santa Clara, California with additional offices in Tel Aviv, Israel; Beijing, China; and Stockholm, Sweden.

MacroGenics

Series B in 2004
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

NeurogesX

Series C in 2004
NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.

Allakos

Series A in 2014
Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.

Aegis Semiconductor

Series B in 2002
Aegis is a privately held company that builds solutions for embedded monitoring of advanced optical networks. The company's Active Thin Films are manufactured using proven high-volume processes with demonstrated high yield and superb uniformity. Aegis's solutions benefit from the reliability of solid-state, silicon-based design, extreme scalability, and low-cost packaging architectures.

ImmuneID

Series A in 2021
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.

ABIONYX Pharma SA

Series C in 2010
ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

ABIONYX Pharma SA

Series B in 2006
ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

Foldrx Pharmaceuticals

Venture Round in 2010
FoldRx Pharmaceuticals, Inc. engages in the discovery and development of disease modifying drug therapies for diseases of protein misfolding and amyloidosis. The companyТs pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, transthyretin-associated amyloidoses with polyneuropathy and TTR-associated amyloidoses with cardiomyopathy, and a discovery program in Parkinson's disease and cystic fibrosis. FoldRx Pharmaceuticals, Inc. was founded in 2003 and is based in Cambridge, Massachusetts.

Tyra Biosciences

Series B in 2021
Tyra Biosciences, Inc. develops small molecule therapies for the treatment of cancer. It offers therapies to combat drug resistance in cancer treatments. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Coapt Systems

Series E in 2007
Coapt Systems, Inc. engages in the design, development, manufacture, and marketing of bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures. It offers ENDOTINE Forehead 3.0, a bioabsorbable brow fixation device; ENDOTINE Forehead Instrument Kits that comprise insertion tools, drill bits, and sterilization trays with lids; ENDOTINE Triple 3.0, the bioabsorbable brow fixation devices with disposable drill bits and insertion tools; ENDOTINE TransBleph 3.0, a bioabsorbable upper lid and brow fixation devices. The company also provides ENDOTINE Midface ST 4.5, a bioabsorbable midface suspension devices; ENDOTINE Ribbon, a bioabsorbable fixation devices; Coapt Manual Surgical Drills, the manual surgical hand drills for use with ENDOTINE implants; and SurgiWire Incisionless Dissectors, the subcutaneous The Endotine product line was bought by MicroAire, a surgical device manufacturer in Charlottesville, VA, in August 2010.
DispatchHealth Management, LLC provides on-demand mobile and virtual healthcare services. It offers services in the areas of acute injury and illness evaluation, laceration suture repair, injured extremity splinting, epistaxis treatment (nosebleeds), Foley catheter placement, G-tube placement, medication administration, laboratory testing, outpatient imaging arrangement (X-ray and CT scan), and primary care physician and home health agency coordination aspects. It serves patients and families. The company was formerly known as True North Health Navigation, LLC. DispatchHealth Management, LLC was founded in 2013 and is based in Denver, Colorado.

Transcarent

Series A in 2020
Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.

Sutro Biopharma, Inc.

Series D in 2013
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Esperion Therapeutics

Venture Round in 2013
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

iSOCO

Venture Round in 2006
iSOCO is an international company that offers business solutions based on the design of cutting-edge technologies and strategic consultation to optimise relations between organisations and customers, suppliers, employees and partners and transform them into economic values. They build collaborative networks that integrate advanced technology which can create communities, facilitate communication, generate knowledge and connect opportunities. iSOCO has been recognised as a Key Vendor 2013 by Gartner for its virtual assistant. Furthermore in one of the spanish companies acredited as a official purchasing auditor into the framework of the new European Standard Purchasing.

Cellective Therapeutics

Series A in 2004
Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.

Xelerated

Series E in 2008
Xelerated Inc. operates as a fabless semiconductor company. The company provides HX devices that offer wirespeed performance and cover a range of applications from carrier backbone platforms to access aggregation and enterprise switching systems; and Xelerator devices, which are network processors. It also offers a Software Development Kit that delivers an integrated development environment for developing, simulating, debugging, and testing forwarding plane applications for Xelerator network processors, as well as supports Xelerated's HX carrier Ethernet network processors and AX programmable Ethernet switches. In addition, the company provides Reference Design Kits, which are network processor development platforms for Xelerator network processors; and Precision Time Solution, which provides hardware and software support for Precision Time Protocol and Synchronous Ethernet. Further, it offers solutions for data aware transport platforms, switches/routers, metro Ethernet switches, and access equipment. The company was formerly known as Xelerated Packet Devices and changed its name to Xelerated Inc. in January 2002. The company was founded in 2000 and is headquartered in Santa Clara, California with additional offices in Tel Aviv, Israel; Beijing, China; and Stockholm, Sweden.

Renovis

Series B in 2002
Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.

Kiadis Pharma N.V.

Venture Round in 2007
Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.

Taligen Therapeutics

Series B in 2010
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process.

eGenesis

Series B in 2019
Egenesis Inc., a biotechnology company, operates as a gene editing and genome engineering that develops human transplantable organs, tissues, and cells. It offers a gene editing platform for developing human compatible organs. The company also provides development, such as gene engineering, single cell cloning, somatic cell nuclear/embryo transfer, organ procurement, and transplantation. The company was incorporated in 2015 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

TransMedics Group, Inc.

Series B in 2004
TransMedics, Inc. operates as a medical technology company. It offers organ care system, a multi-organ preservation technology that mirrors human physiology, minimizes ischemia, and provides the ability to optimize the organ during transport. The company is headquartered in Andover, Massachusetts.

Phenomix

Series A in 2002
As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

Esperion Therapeutics

Series A in 2008
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

SARcode Bioscience

Series B in 2011
SARcode Corporation is a private San Francisco based biopharmaceutical company engaged in the development of a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2) antagonists as a topical agent for the treatment of significant unmet medical needs in ophthalmology, dermatology and other inflammatory diseases.

Anesiva

Series C in 2002
Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management worldwide. Its lead product candidate includes Adlea, which completed multiple Phase II and Phase III trials for post-surgical, musculoskeletal, and neuropathic pain. The company was formerly known as AlgoRx Pharmaceuticals, Inc., it changed its name to Anesiva, Inc. in 2006. Anesiva, Inc. was founded in 1999 and is headquartered in South San Francisco, California. On January 15, 2010, Anesiva, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California. On June 10, 2014 filed for Chapter 7 bankruptcy.

Coapt Systems

Series C in 2003
Coapt Systems, Inc. engages in the design, development, manufacture, and marketing of bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures. It offers ENDOTINE Forehead 3.0, a bioabsorbable brow fixation device; ENDOTINE Forehead Instrument Kits that comprise insertion tools, drill bits, and sterilization trays with lids; ENDOTINE Triple 3.0, the bioabsorbable brow fixation devices with disposable drill bits and insertion tools; ENDOTINE TransBleph 3.0, a bioabsorbable upper lid and brow fixation devices. The company also provides ENDOTINE Midface ST 4.5, a bioabsorbable midface suspension devices; ENDOTINE Ribbon, a bioabsorbable fixation devices; Coapt Manual Surgical Drills, the manual surgical hand drills for use with ENDOTINE implants; and SurgiWire Incisionless Dissectors, the subcutaneous The Endotine product line was bought by MicroAire, a surgical device manufacturer in Charlottesville, VA, in August 2010.

TorreyPines Therapeutics

Series C in 2005
TorreyPines Therapeutics engages in the discovery and development of small molecule compounds in the United States. Its product portfolio includes both candidates from its drug targeting platforms and in-licensed and acquired product candidates. As of August 31, 2010, its pipeline includes three clinical development programs. It also has three other clinical-stage product candidates, for which it is seeking business development partners, and it has four preclinical product candidates it is developing, three of which are based upon its drug-targeting platforms.

Synad Technologies

Series B in 2002
Synad is a fast-growing UK startup that has rapidly revealed itself as one of the most successful WLAN fabless companies and one of the few able to deliver a full dual-band multi-standard solution. Synad has a proven multimode full CMOS production-ready chipset and reference design, and powerful software suites for both wireless-LAN access point and client applications.

NeurogesX

Series A in 2000
NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.

Calistoga Pharmaceuticals

Series C in 2010
Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects. Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.

Xelerated

Series B in 2001
Xelerated Inc. operates as a fabless semiconductor company. The company provides HX devices that offer wirespeed performance and cover a range of applications from carrier backbone platforms to access aggregation and enterprise switching systems; and Xelerator devices, which are network processors. It also offers a Software Development Kit that delivers an integrated development environment for developing, simulating, debugging, and testing forwarding plane applications for Xelerator network processors, as well as supports Xelerated's HX carrier Ethernet network processors and AX programmable Ethernet switches. In addition, the company provides Reference Design Kits, which are network processor development platforms for Xelerator network processors; and Precision Time Solution, which provides hardware and software support for Precision Time Protocol and Synchronous Ethernet. Further, it offers solutions for data aware transport platforms, switches/routers, metro Ethernet switches, and access equipment. The company was formerly known as Xelerated Packet Devices and changed its name to Xelerated Inc. in January 2002. The company was founded in 2000 and is headquartered in Santa Clara, California with additional offices in Tel Aviv, Israel; Beijing, China; and Stockholm, Sweden.

Qihan Biotech

Series A in 2018
Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.

Intarcia Therapeutics

Series E in 2004
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

MacroGenics

Series C in 2006
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Phenomix

Series B in 2005
As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

Lumena Pharmaceuticals

Series B in 2014
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults.

Aegerion Pharmaceuticals

Series A in 2006
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.

Pathwork Diagnostics

Series C in 2010
Pathwork Diagnostics is based in Redwood City, California. The company develops and delivers innovative molecular diagnostics for oncology. The Pathwork Tissue of Origin Test for frozen tissue was the first to receive FDA clearance for a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastic cancer.

Anesiva

Series D in 2003
Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management worldwide. Its lead product candidate includes Adlea, which completed multiple Phase II and Phase III trials for post-surgical, musculoskeletal, and neuropathic pain. The company was formerly known as AlgoRx Pharmaceuticals, Inc., it changed its name to Anesiva, Inc. in 2006. Anesiva, Inc. was founded in 1999 and is headquartered in South San Francisco, California. On January 15, 2010, Anesiva, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California. On June 10, 2014 filed for Chapter 7 bankruptcy.

Cytos

Series B in 2000
Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.

Chimerix, Inc.

Series D in 2007
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

aTyr Pharma, Inc.

Series C in 2010
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Vir Biotechnology, Inc.

Venture Round in 2017
Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.

Agensys

Series C in 2002
Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.

Tacit Software

Venture Round in 2004
Tacit Software is a provider of collaboration and knowledge management software and the company behind illumio (www.illumio.com), a productivity tool for monitoring news, blogs, and wikis and connecting with others to share knowledge and expertise. illumio is used by individuals and organizations to more effectively discover and share information by delivering to users only what's important to them. Tacit's enterprise customers include some of the world's leading Fortune 500 companies including Lockheed Martin, Morgan Stanley, and Northrop Grumman.

nCircle Network Security

Series B in 2001
nCircle Network Security, Inc. provides agentless security risk and compliance management solutions. The company's products include IP360, the vulnerability and risk management solution that provides reporting, vulnerability prioritization, and remediation workflow designed to enable risk reduction; and Topology Risk Analyzer, which prioritizes vulnerabilities utilizing intelligence about the network layout. Its products also include Security Intelligence Hub, an open-architected reporting and integration point for collecting and sharing network intelligence across the enterprise security ecosystem; and nTellect, a threat prioritization system that leverages IP360's updated network intelligence to improve the accuracy and effectiveness of Cisco and McAfee's IDS and IPS. In addition, the company's products include Certified PCI Scan Service, an automated network security scan and reporting service, which enables customers to monitor and report on compliance with the PCI security standard; and Security Policy and Regulatory Compliance Solutions that compliance with internal security policies and automate security process, as well as support government- regulatory compliance solutions for FISMA and IAVA. It also provides configuration and regulatory compliance, reporting and analytics, and government solutions. The company offers vulnerabilities and exposures research team, consulting, and training services. Its security solutions are used by financial services, energy, utilities, retail, consumer goods, healthcare, pharmaceuticals, government, media, leisure, and technology enterprises, as well as government agencies and service providers to identify, measure, manage, and reduce security risk and automate compliance on their networks. The company was formerly known as Hiverworld, Inc. nCircle Network Security, Inc. was founded in 1998 and is headquartered in San Francisco, California with regional offices in Atlanta, Toronto, and London.

Allakos

Series B in 2017
Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.

Aegis Semiconductor

Series C in 2004
Aegis is a privately held company that builds solutions for embedded monitoring of advanced optical networks. The company's Active Thin Films are manufactured using proven high-volume processes with demonstrated high yield and superb uniformity. Aegis's solutions benefit from the reliability of solid-state, silicon-based design, extreme scalability, and low-cost packaging architectures.

VertiFlex

Series B in 2007
VertiFlex, Inc., a medical device company, provides minimally invasive and motion preserving spinal surgery technologies in the United States and internationally. The company offers superion interspinous spacer, a percutaneous titanium implant that fits between the spinous processes in the lumbar spine. Its Superion is a motion-preserving interspinous spacer for the treatment of moderate spinal stenosis. Vertiflex Inc was founded in 2005 and is headquartered in California, USA.

Intradigm Corporation

Series A in 2006
Private biotechnology company that develops systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's expertise in drug development and delivery serves as the foundation of Intradigm RNAi platform. In particular, the company proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product.

Sutro Biopharma, Inc.

Series B in 2007
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

aTyr Pharma, Inc.

Series E in 2015
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Aegerion Pharmaceuticals

Convertible Note in 2008
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.

Evofem Biosciences

Series C in 2014
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.